CORONA vs SAKAR: Stock Comparison
CORONA REMEDIES is the larger company by market capitalisation. CORONA REMEDIES shows a higher ROE, a higher dividend yield and lower leverage, while SAKAR HEALTHCARE shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CORONA leads 6; SAKAR leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | CORONA | SAKAR |
|---|---|---|
| Sector | — | Healthcare |
| Industry | — | Pharmaceuticals |
Price
| Metric | CORONA | SAKAR |
|---|---|---|
| Live Price | ₹2,010 | ₹923.2 |
| Day Change | 0.3% | -4% |
| Volume | 17,444 | 66,081 |
| 52-Week High | ₹2,292.4 | ₹1,229.85 |
| 52-Week Low | ₹1,336.6 | ₹350.1 |
| Distance from 52W High | -12.32% | -24.93% |
Valuation
| Metric | CORONA | SAKAR |
|---|---|---|
| Market Cap | ₹12,313 Cr | ₹2,047 Cr |
| P/E Ratio | 61.87x | 56.71x |
| P/B Ratio | 16.49x | 6.31x |
| EPS | ₹9.83 | ₹4.62 |
| Book Value | ₹122.12 | ₹128.3 |
| Dividend Yield | 0.5% | 0% |
Growth
| Metric | CORONA | SAKAR |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 40.1% |
| EPS Growth (TTM YoY) | 0% | 87.2% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | CORONA | SAKAR |
|---|---|---|
| ROE | 24.28% | 10.68% |
| ROCE | 20.94% | 10.13% |
| Net Margin | 13.19% | 12.11% |
| Operating Margin | 15.89% | 18.91% |
| Debt to Equity | 0.19x | 0.26x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | CORONA | SAKAR |
|---|---|---|
| Promoter Holding | 69% | 51.7%▼ 0.82 pp |
| FII Holding | 4.21%▲ 0.58 pp | 12.34%▲ 0.21 pp |
| DII Holding | 16.45%▲ 3.55 pp | 11.92%▲ 0.55 pp |
| Public Holding | 10.34%▼ 4.14 pp | 24.04%▲ 0.06 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CORONA REMEDIES and SAKAR HEALTHCARE.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.